
New chairman for Leukemia & Lymphoma Society
pharmafile | July 18, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Leukemia & Lymphoma. jim davis
James Davis has been elected chairman of the national board of directors of The Leukemia & Lymphoma Society (LLS).
Davis is the former executive VP, general counsel and secretary of Human Genome Sciences, a biopharma firm that pioneered new treatments in the areas of auto-immune diseases, cancer, and bioterrorism.
His professional background has focussed on the intersection of science, business, and law, particularly in issues related to the commercialisation of new technologies.
Davis, who will serve a two-year term as chair, is also a chronic myeloid leukaemia (CML) patient and clinical trial participant. He has served in several capacities with LLS, starting in 2007, including vice-chair of the board of directors, chair of the mission oversight committee, and as a member of the Therapy Acceleration Program (TAP) medical & scientific affairs and executive committees.
“It’s an honor to be elected to this position by my colleagues on the board,” says Davis. “I look forward to working with the board to help advance the LLS mission.”






